Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 6/20 | 0.74 |
| ▸ | LAP3 | P28838 | 1/20 | 0.62 |
| ▸ | PPARG | P37231 | 4/20 | 0.60 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 2/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.55 |
| ▸ | EPOR | P19235 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6162332 | 1.00 | LTA4H (0.74) | LTA4HLAP3PPARGLNPEPMAOB | |
| SCHEMBL7921142 | 1.00 | LTA4H (0.74) | LTA4HLAP3PPARGLNPEPMAOB | |
| Hydrochloric Acid SCHEMBL3497991 | 0.99 | LTA4H (0.73) | LTA4HLAP3PPARGLNPEPMAOB | |
| Hydrochloric Acid SCHEMBL3499496 | 0.99 | LTA4H (0.73) | LTA4HLAP3PPARGLNPEPMAOB | |
| Hydrochloric Acid SCHEMBL3497988 | 0.99 | LTA4H (0.73) | LTA4HLAP3PPARGLNPEPMAOB | |
| Phenylalanine Methyl Ester SCHEMBL28633098 | 0.96 | LTA4H (0.70) | LTA4HLAP3PPARGLNPEPPPARA | |
| Butylamine SCHEMBL8391542 | 0.91 | LTA4H (0.63) | LTA4HLAP3PPARGLNPEPEPOR | |
| SCHEMBL16607620 | 0.90 | LTA4H (0.67) | LTA4HLAP3PPARGLNPEPMAOB | |
| SCHEMBL6561218 | 0.89 | LTA4H (0.73) | LTA4HLAP3PPARGLNPEPMAOB | |
| SCHEMBL1855604 | 0.89 | LTA4H (0.73) | LTA4HLAP3PPARGLNPEPMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | SERVIER LAB (FR) | 2026-01-01 | — | — | US | disclosed |
| EP-4551566-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Les Laboratoires Servier (FR) | 2025-05-14 | — | — | EP | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| WO-2024044549-A1 | VHH ANTIBODY CONJUGATES | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| WO-2024008941-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2024-01-11 | — | — | WO | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| CN-102659617-B | L-tyrosine derivative, medicine compound and application thereof | UNIV TIANJIN MEDICAL | 2014-05-21 | — | — | CN | disclosed |
| WO-1999006433-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| EP-0888317-A1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LIMITED (GB) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997031907-A1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LIMITED (GB) | 1997-09-04 | — | — | WO | disclosed |
| EP-0770063-A1 | TECHNETIUM-SULPHONAMIDE COMPLEXES, THEIR USE, PHARMACEUTICAL AGENTS CONTAINING THEM, AND PROCESS FOR PRODUCING THE COMPLEXES AND AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996022962-A9 | BUTYRYL-TYROSINYL SPERMINE, ANALOGS THEREOF AND METHODS OF PREPARING AND USING SAME | — | 1996-10-03 | — | — | WO | disclosed |
| WO-1996022962-A1 | BUTYRYL-TYROSINYL SPERMINE, ANALOGS THEREOF AND METHODS OF PREPARING AND USING SAME | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1996-08-01 | — | — | WO | disclosed |
| WO-1996002500-A1 | TECHNETIUM-SULPHONAMIDE COMPLEXES, THEIR USE, PHARMACEUTICAL AGENTS CONTAINING THEM, AND PROCESS FOR PRODUCING THE COMPLEXES AND AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-02-01 | — | — | WO | disclosed |
| CN-1112364-A | Piperazine derivatives and salts thereof | OTSUKA PHARMA CO LTD (JP) | 1995-11-22 | — | — | CN | disclosed |
| US-4574079-A | Radiolabeled angiotensin converting enzyme inhibitors for radiolabeling mammalian organ sites | BOSTON UNIVERSITY, A NOT FOR PROFIT CORP | 1986-03-04 | — | — | US | disclosed |
| EP-0030845-A2 | Pharmacologically active peptides, their preparation and pharmaceutical compositions containing them | ELI LILLY AND COMPANY (US) | 1981-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BCL2A1, BAX | LTA4H 3870/4885LAP3 2378/4885PPARG 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.